Enanta Pharmaceuticals (FRA:9EP) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9EP Enanta Pharmaceuticals Inc FRA:9EP
58 GF Score
Price €11.10
GF Value €7.46
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Enanta Pharmaceuticals Quality Rank Related Terms

FRA:9EP
58GF Score
Enanta Pharmaceuticals Inc FRA:9EP
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Enanta Pharmaceuticals (FRA:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €11.10 is trading 48.8% above its estimated GF Value™ of €7.46. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:9EP:

  • Quality Rank:
  • GF Value™: €7.46 vs. price of €11.10 (48.8% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score

Get the complete analysis for FRA:9EP

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.10
Price
€7.46
GF Value